DEPRODONE PROPIONATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32O5
Molecular Weight	400.5079
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(C)=O

InChI

InChIKey=DRSFVGQMPYTGJY-GNSLJVCWSA-N

InChI=1S/C24H32O5/c1-5-20(28)29-24(14(2)25)11-9-18-17-7-6-15-12-16(26)8-10-22(15,3)21(17)19(27)13-23(18,24)4/h8,10,12,17-19,21,27H,5-7,9,11,13H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407

Deprodone is a steroid that was approved in Japan for the treatment of inflammatory skin disorders. The drug is marketed under the name Eclar and contains 0.3% of the prodrug, deprodone propionate.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Inflammatory skin diseases 5 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	Primary		Approved 8583	ECLAR Approved Use It is usually used to treat eczema, dermatitis, drug eruption, insect sting, prurigo, psoriasis, erythroderma, erythema, palmoplanter pustulosis, alopecia areata, etc.

Doses

Dose	Population	Adverse events
0.3 % 1 times / day multiple, topical Recommended Dose: 0.3 %, 1 times / day Route: topical Route: multiple Dose: 0.3 %, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	Disc. AE: Ocular hypertension, Posterior capsule opacification... Other AEs: Glaucoma... AEs leading to discontinuation/dose reduction: Ocular hypertension Posterior capsule opacification Other AEs: Glaucoma Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407

AEs

AE	Significance	Dose	Population
Glaucoma		0.3 % 1 times / day multiple, topical Recommended Dose: 0.3 %, 1 times / day Route: topical Route: multiple Dose: 0.3 %, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407
Ocular hypertension	Disc. AE	0.3 % 1 times / day multiple, topical Recommended Dose: 0.3 %, 1 times / day Route: topical Route: multiple Dose: 0.3 %, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407
Posterior capsule opacification	Disc. AE	0.3 % 1 times / day multiple, topical Recommended Dose: 0.3 %, 1 times / day Route: topical Route: multiple Dose: 0.3 %, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407

Patents

Sample Use Guides

In Vivo Use Guide

Deprodone (ointment or cream containing 0.3% deprodone propionate) is applied to the affected area, once to several times a day.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Name

Type

Language

ALLOMIDON

Preferred Name

English

DEPRODONE PROPIONATE

Common Name

English

DEPRODONE PROPIONATE [JAN]

Common Name

English

Deprodone propionate [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

443972